Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (Month 7) [clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2]

Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (Month 7) [clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2]

V419 + DAPTACEL™ + PedvaxHIB™ + Prevnar 13™ + RotaTeq™
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005 AM4) [clinicaltrials:NCT01337167]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (Month 7) [clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2]

V419 + DAPTACEL™ + PedvaxHIB™ + Prevnar 13™ + RotaTeq™
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2
Bio2RDF identifier
d0d5a7ab338f3c4b1d7d2c669cf560e2
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2
measure [clinicaltrials_vocabulary:measure]
Number of responders to polyribosylribitol phosphate (PRP) antigen
time frame [clinicaltrials_vocabulary:time-frame]
description
V419 + DAPTACEL™ + PedvaxHIB™ + Prevnar 13™ + RotaTeq™
identifier
clinicaltrials_resource:d0d5a7ab338f3c4b1d7d2c669cf560e2
title
Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (Month 7)
@en
inDataset
type
label
Number of responders to polyri ...... 5a7ab338f3c4b1d7d2c669cf560e2]
@en